Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
22.45
-0.42 (-1.84%)
Jan 23, 2025, 12:39 PM EST - Market open
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $128.70M in the quarter ending September 30, 2024, with 25.33% growth. This brings the company's revenue in the last twelve months to $460.48M, up 32.17% year-over-year. In the year 2023, Catalyst Pharmaceuticals had annual revenue of $398.20M with 85.90% growth.
Revenue (ttm)
$460.48M
Revenue Growth
+32.17%
P/S Ratio
5.72
Revenue / Employee
$2,757,377
Employees
167
Market Cap
2.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | 102.31M | 101.81M | 20,361.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CPRX News
- 3 hours ago - Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies - GlobeNewsWire
- 2 days ago - Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - GlobeNewsWire
- 10 days ago - Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE - Seeking Alpha
- 14 days ago - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals - GlobeNewsWire
- 5 weeks ago - Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - GlobeNewsWire